Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
DePuy Hip Failure Rate Estimated at 37% Following Recall: Report January 23, 2013 Austin Kirk Add Your Comments According to an internal analysis by a Johnson & Johnson subsidiary, the medical device manufacturer estimated that nearly 40% of all recalled DePuy ASR hips would fail within five years of being implanted. A report by the New York Times on Tuesday described recently released documents, which indicate that Johnson & Johnson determined that the DePuy ASR hip failure rates may be substantially higher than were indicated at the time the company removed the metal-on-metal implant from the market. When the DePuy ASR recall was issued in August 2010, the manufacturer indicated that data suggested between 12% and 13% of the hip implants were failing within five years. However, the New York times reports that the company’s own analysis estimated that 37% of individuals who received the implant were likely to experience problems with loosening or failure of the component. Learn More About Hip Replacement Lawsuits If you or a loved one experienced complications or needed revision surgery due to a defective hip implant, you may be entitled to financial compensation. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Hip Replacement Lawsuits If you or a loved one experienced complications or needed revision surgery due to a defective hip implant, you may be entitled to financial compensation. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The estimates are similar to numbers reported in a British implant registry, which the manufacturer has previously attempted to downplay publicly. Unlike traditional hip implants, the DePuy ASR features an all-metal chromium and cobalt design. According to allegations raised in the lawsuits, problems with the DePuy ASR hip may occur as microscopic metal particles are released into the body as the metal parts rub against each other. This could resulted in metal blood poisoning or metallosis, which increases the risk of the device loosening or failing, according to allegations raised in lawsuits filed by individuals throughout the United States. First DePuy ASR Hip Lawsuit Trial To Begin The records have come to light as the first DePuy ASR hip lawsuit prepares to go before a jury this week, in what will be the first trial out of more than 10,000 cases pending against the medical device manufacturer by individuals who experienced problems from the metal-on-metal implant. Trial is scheduled to begin on Friday in California Superior Court in Los Angeles, involving a lawsuit filed by Loren and Sheryl Kransky. The case received an expedited trial date because Loren is suffering a terminal cancer. The case is expected to involve dozens of witnesses and will be closely followed by all DePuy hip replacement lawyers involved in the lawsuits, as the outcome may help the parties gauge how juries in other cases are likely to respond to evidence and testimony that will be repeated throughout the litigation. The outcome may help the facilitate additional negotiations to settle the DePuy hip lawsuits. A settlement agreement was reached in an earlier DePuy ASR case, which was scheduled for trial to begin in December in Nevada state court. Last week, Bloomberg News reported that Johnson & Johnson has offered to pay more than $200,000 to settle each DePuy ASR case, which could result in a total payment of more than $2 billion to resolve the litigation. However, attorneys involved in the lawsuits have reportedly rejected the offers so far, indicated that they do not provide sufficient compensation for injuries caused by the recalled hip. DePuy Internal Analysis Revealed High Failure Rate for DePuy Hip At the time of the DePuy ASR was removed from the market, DePuy Orthopaedics publicly stated that they estimated the hip replacement failure rate was about one out of every eight implants within five years. A subsequent analysis by the National Joint Registry for England and Wales in September 2011 found that the implants appeared to have a 29% failure rate after only six years. However, it now appears that the manufacturer’s own analysis around the same time suggests that data was actually conservative. DePuy Orthopaedics reportedly conducted an analysis of ASR hip failures in 2011, about a year after the DePuy ASR metal hip implant recall. While company officials have suggested that their analysis was small and could not be used to generalize total ASR artificial hip failure rates, it appears that their internal estimates suggested that more than one out of every three hip replacements could fail within five years. Tags: California, DePuy, Depuy ASR Hip, Johnson & Johnson, Metal-on-Metal Hip Replacement, Metallosis Image Credit: | More Hip Replacements Lawsuit Stories Biomet Hip Lawsuit Filed Over Defective M2A Metal-on-Metal Implant December 26, 2024 Zimmer Biomet Lawsuit Filed Over RibFix Blu Implant Fracture September 25, 2024 Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns September 18, 2024 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025) Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025) Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns September 18, 2024
Oxbryta Settlement Discussions in Class Action Lawsuits Set for Sept. 2025 (Posted: today) A mediator has been appointed to oversee settlement discussions between parties involved in an Oxbryta class action lawsuit, which claims the recalled drug endangered sickle cell disease patients. MORE ABOUT: OXBRYTA LAWSUITWrongful Death Lawsuit Links Oxbryta Side Effects to Deadly Vaso-Occlusive Crises (06/05/2025)Oxbryta Recall Lawsuit Alleges Sickle Cell Drug Increased Frequency of Dangerous VOCs (05/23/2025)First Oxbryta Lawsuit Set for Trial in August 2027, Over Recalled Sickle Cell Drug Risks (05/09/2025)
Lawsuit Indicates Biozorb Side Effects Left Woman With Chronic Pain, Disfiguring Injuries (Posted: yesterday) A BioZorb side effects lawsuit indicates that a woman is suffering chronic pain and soreness after the tissue marker implant failed to absorb into her body as advertised. MORE ABOUT: BIOZORB LAWSUITBioZorb Implant Removal Surgery: What Women Need To Know When the Device Fails To Dissolve (06/30/2025)Lawsuit Claims Biozorb Implant Penetrated Skin, Causing Massive Infection (06/04/2025)Breast Cancer Survivors File BioZorb Tissue Marker Lawsuit After Implant Fails (05/20/2025)
Second Wave of Valsartan Cancer Lawsuits To Be Ready for Bellwether Trials by January 2026 (Posted: yesterday) A new schedule for a second wave of Valsartan cancer lawsuit bellwether trials hopes to have a case ready to go before a jury by January 2026. MORE ABOUT: VALSARTAN LAWSUITCourt Outlines Valsartan Lawsuits Trial Schedule for “Wave 2” Bellwether Cases (05/28/2025)Order Requires Valsartan Recall Lawsuits To Provide Product Identification for Specific Generic Drug Makers Named (03/27/2025)Deadlines Leading to First Valsartan Bellwether Trial on Sept. 8, 2025 Outlined by Special Master (03/04/2025)